Want to see SE:IMMNOV full AI Analyst Report?
IMMNOV Stock Chart & Stats
kr0.23
-kr0.02(-4.98%)
At close: 4:00 PM EST
kr0.23
-kr0.02(-4.98%)
Day’s Range― - ―
52-Week Rangekr0.15 - kr0.75
Previous CloseN/A
Volume868.16K
Average Volume (3M)5.10M
Market Cap
kr124.31M
Enterprise Valuekr60.09
Total Cash (Recent Filing)kr56.09M
Total Debt (Recent Filing)kr479.00K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 06, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding672,666,900
10 Day Avg. Volume6,199,351
30 Day Avg. Volume5,096,607
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)kr4.40M
Bulls Say, Bears Say
Bulls Say
Focused Diagnostic NicheImmunovia’s exclusive focus on immunoassay biomarker tests for earlier pancreatic cancer detection targets a large unmet clinical need. That specialization supports durable clinical partnerships, focused R&D, and clearer regulatory/market pathways versus diversified peers, aiding long-term adoption.
Low Financial LeverageVery low debt materially reduces refinancing and interest-rate risk and gives the company optionality when raising capital for commercialization. A light leverage profile provides structural balance sheet flexibility while it attempts to reach sustainable revenue and profitability.
Positive Recent Top-line TrendDespite small absolute revenues, recent TTM and reported revenue growth indicate early commercial traction and potential for scaling diagnostic uptake. If sustained, this trend supports higher utilization, learning curves, and potential margin improvement over multiple quarters.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-80M TTM) indicates ongoing cash burn that will require repeated external funding. Chronic cash deficits constrain long-term investments, increase dilution risk, and place pressure on execution of commercialization and regulatory programs.
Negative Unit EconomicsNegative gross profit implies the core test currently loses money on a per-unit basis, meaning scaling revenue alone may not deliver profit without cost redesign or pricing changes. Persistently unprofitable unit economics threaten sustainable margins and long-term viability.
Eroding Equity BaseMaterial declines in shareholder equity from cumulative losses weaken the balance sheet cushion, reducing resilience to future setbacks. A shrinking capital base increases dependence on new financing and raises execution risk for product rollout and regulatory advancement.
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.15 and its highest was kr0.75 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr124.31M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on May 07, 2026. The company reported -kr0.03 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.04.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 17.143%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Technical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―